Advertisement
Advertisement
RNA
Atrium Therapeutics, Inc. Common Stock
12.11
USDSponsored
+0.37
+3.15%
Aug 06, 16:00 UTC -4
Closed
After-Market
12.13
+0.03
+0.21%
RNA Earnings Reports
Positive Surprise Ratio
RNA beat 13 of 23 last estimates.
57%
Next Report
Date of Next Report
--
Estimate for Q-- -- (Revenue/ EPS)
--
/--
Implied change from Q2 26 (Revenue/ EPS)
--
/--
Implied change from Q-- -- (Revenue/ EPS)
--
/--
Atrium Therapeutics, Inc. Common Stock earnings per share and revenue
On Aug 05, 2026, RNA reported earnings of -- USD per share (EPS) for Q2 26, -- the estimate of -1.32 USD, resulting in a --% surprise. Revenue reached --, compared to an expected 2.80 million, with a --% difference.
Looking ahead to -- --, -- analysts forecast an EPS of -- USD, with revenue projected to reach -- USD, implying an -- of --% EPS, and -- of --% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
MBX Biosciences, Inc. Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.63
Actual
-$0.78
Surprise
-22.16%
Monte Rosa Therapeutics, Inc. Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.39
Actual
-$0.43
Surprise
-9.58%
Corvus Pharmaceuticals, Inc.
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.16
Actual
-$0.19
Surprise
-17.36%
Cullinan Therapeutics, Inc. Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.82
Actual
-$0.81
Surprise
+1.94%
Prime Medicine, Inc. Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.26
Actual
-$0.24
Surprise
+8.57%
Prothena Corporation plc Ordinary Shares
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.39
Actual
-$0.32
Surprise
+19.76%
X4 Pharmaceuticals, Inc. Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.18
Actual
-$0.13
Surprise
+29.19%
SAB Biotherapeutics, Inc. Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.29
Actual
-$0.28
Surprise
+5.15%
Cytokinetics Inc.
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$1.67
Actual
-$1.50
Surprise
+10.35%
Ligand Pharmaceuticals Inc.
Report Date
Aug 06, 2026 For Q2 26
Estimate
$1.90
Actual
$2.37
Surprise
+24.56%
FAQ
What were Atrium Therapeutics, Inc. Common Stock's earnings and revenue for the latest quarter Q2 2026?
For Q2 2026, Atrium Therapeutics, Inc. Common Stock reported EPS of --, missing estimates by --, and revenue of --, -- -- expectations.
How did the market react to Atrium Therapeutics, Inc. Common Stock's Q2 2026 earnings?
The stock price moved -- --, changed from -- before the earnings release to -- the day after.
When is Atrium Therapeutics, Inc. Common Stock expected to report next?
The next earning report is scheduled for --.
What are the forecasts for Atrium Therapeutics, Inc. Common Stock's next earnings report?
Based on --
analysts, Atrium Therapeutics, Inc. Common Stock is expected to report EPS of -- and revenue of -- for Q-- --.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement